Grand Pharmaceutical Group Limited (00512.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.03

From 52W high−47.36%

Volume7.02M

Market capHKD 17.12B

P/E (TTM)15.2x

P/S (TTM)1.4x

Div yield3.46%

Key dataSep 18, 2026

Open

HKD 5.03

From 52W high

−47.36%

Volume

7.02M

Market cap

HKD 17.12B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.1x

P/E (TTM)

15.2x

RSI (14)

43.0

MomentumView details →

1D Return

−1.11%

YTD Return

−37.77%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

15.2x

EV/EBITDA

9.1x

EV/Sales

1.7x

P/S (TTM)

1.4x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

52.11%

Net Margin

9.02%

EBITDA Margin

18.47%

ROE (TTM)

6.57%

ROA (TTM)

4.03%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

+7.35%

EPS YoY

−45.68%

FCF YoY

−9.47%

Revenue CAGR 3Y

+8.71%

EPS CAGR 3Y

−15.98%

EBITDA YoY

−17.03%

MomentumView details →

1D Return

−1.11%

YTD Return

−37.77%

1Y Return

−43.79%

RSI (14)

43.0

vs 50D SMA

−5.03%

vs 200D SMA

−23.76%

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

1.34x

Quick Ratio

1.10x

Div Yield

3.46%

Div Rate

HKD 0.17

Div Growth 1Y

−35.00%

EarningsView details →

EPS (Actual)

HKD 0.28

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

24.27B

Net Income (TTM)

3.21B

Op. CF (TTM)

3.08B

Next earningsMar 17, 2027 →

Latest newsMore news →

Grand Pharmaceutical's traditional Chinese medicine innovative drug GPN01360 completed first patient dosing in a Phase III clinical study in China for depression.59d ago

Similar companies

健康元600380.SH 华润双鹤600062.SH Livzon Pharmaceutical Group Inc.01513.HK 步长制药603858.SH HUTCHMED (China) Limited00013.HK Fujian Haixi Pharmaceuticals Co., Ltd.02637.HK Find similar companies →

Latest newsMore news →

Grand Pharmaceutical's traditional Chinese medicine innovative drug GPN01360 completed first patient dosing in a Phase III clinical study in China for depression.59d ago